Despite many studies linking dopamine receptors and their genetic polymorphisms with schizophrenia and its clinical manifestation, including the age of onset, cognitive functions, positive and negative symptom severity, treatment response and adverse effects, there is still a relative paucity of research investigating direct associations between DRD2 polymorphisms and the deficit syndrome. The gene discussed is DRD2; the disease is schizophrenia.